Researchers from the Massachusetts General Hospital have discovered a possible autism link in young adults being treated for alcohol or drug use, may in fact be misdiagnosed and on the autism spectrum.
The study, which was published in The American Journal on Addictions last month, found that 20% of patients, or 1 in 5 young adults with an average age of 18.7 who were all being treated in a substance misuse clinic, had elevated scores of the Social Responsiveness Scale-2.
The measuring scale is used to identify the presence and severity of social impairment, which is common to distinguish autism from other disorders.
James McKowen of the Addiction Recovery Management Service at MGH and Harvard Medical School said it is the first study to look at the prevalence of undiagnosed autistic traits among teens and young adults.
“Usually studies of substance-use disorder in autism are done in those with an autism diagnosis already.
“We have looked at this question from the other side, asking how many people with substance-use disorder have autism,” said McKowen.
Researchers from the project asked parents of 69 young adults reporting for the first time to the substance misuse clinic to fill out a SRS-2 form.
They found that although there were few differences between those with elevated autistic trait scores and those with lower, non-autistic scores in terms of demographic or psychiatric factors, the teens with higher SRS-2 scores had a nearly eightfold greater likelihood of stimulant-use disorder, and a fivefold higher risk for opioid-use disorder.
The study highlights the importance of assessing future patients who receive treatment for substance misuse to be screened for autistic traits.
“For clinicians, the big takeaway point from this study is that we need to get better at screening and certainly training in the presence of autism-spectrum disorder, because many clinicians treat substance-use disorder but don’t have specialty developmental training, particularly for issues around autism,” McKowen added.
His research team are developing a free clinical therapy protocol that can help clinicians better address patients with undiagnosed autistic traits.
